Search results
What Is Beta Thalassemia?
Health via Yahoo News· 3 months agoBeta thalassemia is a blood disorder affecting the production of hemoglobin, the iron-rich protein in red blood cells that carries oxygen through the...
Understanding the Beta Thalassemia Minor Trait
Verywell Health via Yahoo News· 9 months agoBeta thalassemia minor—also known as beta thalassemia trait or B thalassemia—is a blood disorder. It lowers your blood's level of hemoglobin, an...
Is Bluebird Bio Stock a Buy?
Motley Fool via Yahoo Finance· 2 hours agoBeing a highly innovative company isn't a sufficient condition for success in the biotech industry. Bluebird Bio (NASDAQ: BLUE), a small-cap gene-editing...
Column: This life-saving drug will cost a record $2.8 million. Who will pay the price?
LA Times via Yahoo Finance· 2 years agoA nurse sets up an IV line. A number of genetics-based treatments are expected to wash up on...
Bluebird bio's blood disorder therapy effective - FDA staff
Reuters via Yahoo News· 2 years agoBluebird bio's blood disorder treatment demonstrates "clinically meaningful" benefit in patients,...
FDA approves $2.8m gene therapy treatment for rare blood disorder
The Hill via AOL· 2 years agoThe Food and Drug Administration (FDA) on Wednesday approved the first gene therapy treatment that...
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
Motley Fool via Yahoo Finance· 5 months agoCRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The...
FDA Advisory Committee Backs Bluebird Bio's Blood Disorder Gene Therapy
Benzinga via Yahoo Finance· 2 years agoThe FDA's Advisory Committee has unanimously backed Bluebird bio Inc's (NASDAQ: BLUE) gene therapy...
Here Are the New Drugs and Treatments We Could See in 2024
Time via Yahoo News· 4 months agoCredit - Getty Images 2023 was a strong year for innovative new drugs, with new medications for...
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
Motley Fool· 1 year agoEditas Medicine (NASDAQ: EDIT) sits at the bleeding edge of biotech's hottest field, gene editing to...
